Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2017 Filed Jan 2, 2018 22:50 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Employee Director Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0000874015-18-000001 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2023-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 22:50 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 3,000 | $50.56 | $151,680.00 |
DisclosureSEC source: 0000874015-18-000001 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.39 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 22:50 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 3,000 | $28.47 | $85,410.00 |
DisclosureSEC source: 0000874015-18-000001 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:27 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNonEmployee Director stock option (right to buy) · Derivative | 3,000 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0000874015-17-000074 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2023-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:27 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 3,000 | $51.69 | $155,070.00 |
DisclosureSEC source: 0000874015-17-000074 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.135 to $52.060, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:27 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 3,000 | $28.47 | $85,410.00 |
DisclosureSEC source: 0000874015-17-000074 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 5,000 | $52.55 | $262,750.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.34 to $52.65, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 5,000 | $10.29 | $51,450.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 4,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 4,000 | $57.00 | $228,000.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 4,000 | $10.29 | $41,160.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 01, 2017 Filed Dec 2, 2017 00:03 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-17-000069 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Underlying: Common Stock · 1,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 2, 2017 00:03 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
SaleCommon Stock | 1,000 | $55.50 | $55,500.00 |
DisclosureSEC source: 0000874015-17-000069 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,433 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.45 to $55.55, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 01, 2017 Filed Dec 2, 2017 00:03 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionCommon Stock | 1,000 | $10.82 | $10,820.00 |
DisclosureSEC source: 0000874015-17-000069 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| November 30, 2017 Filed Dec 2, 2017 00:04 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0000874015-17-000070 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 3,000 shares Expires 2023-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2017 Filed Dec 2, 2017 00:04 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 3,000 | $53.55 | $160,650.00 |
DisclosureSEC source: 0000874015-17-000070 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 30, 2017 Filed Dec 2, 2017 00:04 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 3,000 | $28.47 | $85,410.00 |
DisclosureSEC source: 0000874015-17-000070 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 6,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 6,000 | $53.02 | $318,120.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.75 to $53.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 6,000 | $10.29 | $61,740.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 7,000 | $54.35 | $380,450.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.02 to $54.58, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 7,000 | $10.29 | $72,030.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Employee Director Stock Option (right to buy) · Derivative | 2,812 | $0.00 Strike: $12.94 | $0.00 |
DisclosureSEC source: 0000874015-17-000067 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,812 shares Expires 2022-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 2,812 | $12.94 | $36,387.28 |
DisclosureSEC source: 0000874015-17-000067 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:57 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Employee Director Stock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0000874015-17-000067 · edgar.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 2,250 shares Expires 2023-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:57 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 2,250 | $53.56 | $120,510.00 |
DisclosureSEC source: 0000874015-17-000067 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 22:57 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 2,250 | $28.47 | $64,057.50 |
DisclosureSEC source: 0000874015-17-000067 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 23:29 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 3,000 | $55.39 | $166,170.00 |
DisclosureSEC source: 0000874015-17-000066 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/11/2017. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/11/2017. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:20 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-17-000065 · edgar.xml · derivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:20 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
SaleCommon Stock | 1,000 | $58.35 | $58,350.00 |
DisclosureSEC source: 0000874015-17-000065 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,433 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.20 to $58.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:20 UTC |
O'NEIL PATRICK R.SVP, Legal & General Counsel
|
Exercise / conversionCommon Stock | 1,000 | $10.82 | $10,820.00 |
DisclosureSEC source: 0000874015-17-000065 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP, Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/30/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:35 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,250 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000064 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,250 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:35 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 12,250 | $65.00 | $796,250.00 |
DisclosureSEC source: 0000874015-17-000064 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,041 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:35 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionCommon Stock | 12,250 | $10.29 | $126,052.50 |
DisclosureSEC source: 0000874015-17-000064 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · derivative · entry 6 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,167 Underlying: Common Stock · 8,333 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant of 1/2/2014 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2015. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 20,625 shares per year. Following this transaction, the option was exercisable as to 69,010 on 10/18/2017. F2 · derivative.expiration_date: Grant of 1/2/2014 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2015. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 20,625 shares per year. Following this transaction, the option was exercisable as to 69,010 on 10/18/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,785 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · derivative · entry 5 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,785 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
SaleCommon Stock | 8,333 | $65.00 | $541,645.00 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · nonDerivative · entry 4 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,741 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
Exercise / conversionCommon Stock | 8,333 | $39.87 | $332,236.71 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · nonDerivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
SaleCommon Stock | 7,785 | $65.00 | $506,025.00 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,741 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 21:34 UTC |
PARSHALL B LYNNEDirector · COO
|
Exercise / conversionCommon Stock | 7,785 | $14.69 | $114,361.65 |
DisclosureSEC source: 0000874015-17-000063 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/8/2017. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 904 Underlying: Common Stock · 1,500 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,642 Underlying: Commo Stock · 15,000 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 1,500 | $59.46 | $89,190.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,062 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.40 to $59.52, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 1,500 | $7.25 | $10,875.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 6/17/2016. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
SaleCommon Stock | 15,000 | $59.46 | $891,900.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,014 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.40 to $59.52, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 15,000 | $14.69 | $220,350.00 |
DisclosureSEC source: 0000874015-17-000062 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/17/2016. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,035 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000061 · edgar.xml · derivative · entry 7 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,035 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 21:36 UTC |
Geary Richard SSVP, Development
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 426 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000061 · edgar.xml · derivative · entry 6 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 426 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.